BCR-ABL PEMs have been reported previously in newly diagnosed CP-CML patients in some studies [14]–[15], [17], [20], [31], whereas others failed to detect any mutations in CP-CML patients before treatment initiation despite using sensitive techniques [18]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.